Frankfurt - Delayed Quote EUR

Xenon Pharmaceuticals Inc. (XP0.F)

26.20

-0.20

(-0.76%)

As of 8:02:54 AM GMT+2. Market Open.

Xenon to Present at the 2025 RBC Capital Markets Global Healthcare Conference

VANCOUVER, British Columbia and BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the 2025 RBC Capital Markets Global Healthcare Conference taking place in New York, NY from May 20-21, 2025. Fireside Chat Presentation Details: Date: Wednesday, May 21, 2025 Time: 10:

GlobeNewswire yesterday

XENE
Why Xenon Pharmaceuticals Inc. (XENE) Declined on Tuesday

We recently published an article titled Massive Sell-Offs Just Hit These 10 Stocks Today. In this article, we are going to take a look at where Xenon Pharmaceuticals Inc. (NASDAQ:XENE) stands against the other stocks. Wall Street’s main indices finished mixed on Tuesday, as investors digested the country’s latest inflation figures, which came out lower than […]

Insider Monkey yesterday

XENE

^GSPC
Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus

XENE incurs narrower-than-estimated first-quarter 2025 loss. Studies on lead candidate, azetukalner, in epilepsy and MDD are progressing well.

Zacks 2 days ago

XENE
Xenon Pharmaceuticals Inc (XENE) Q1 2025 Earnings Call Highlights: Strong Financial Position ...

Xenon Pharmaceuticals Inc (XENE) reports robust cash reserves and advances in epilepsy and psychiatry studies, despite minor timeline adjustments.

GuruFocus.com 3 days ago

XENE
Xenon Pharmaceuticals: Q1 Earnings Snapshot

BURNABY, British Columbia (AP) — Xenon Pharmaceuticals Inc. XENE) on Monday reported a loss of $65 million in its first quarter. On a per-share basis, the Burnaby, British Columbia-based company said it had a loss of 83 cents.

Associated Press Finance 3 days ago

XENE
Xenon Reports First Quarter 2025 Financial Results and Provides Business Update

– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment expected to complete in the next few months with topline data anticipated in early 2026 – Phase 3 azetukalner X-NOVA3 MDD and Phase 3 BPD studies on track to initiate mid-year – Results from completed Mount Sinai IST in MDD confirm azetukalner drug activity as seen in X-NOVA – Phase 1 study in healthy volunteers initiated for follow-on Kv7 channel opener XEN1120 – IND filing and Phase 1 study start for XEN1701, lead Nav1.7 candidate, an

GlobeNewswire 3 days ago

XENE
Xenon to Report Q1 2025 Financial Results on May 12, 2025

VANCOUVER, British Columbia and BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its first quarter 2025 financial results and provide a business update after the close of U.S. financial markets on Monday, May 12, 2025. Conference Call/Webcast Information: Date:Monday, May 12, 2025 T

GlobeNewswire 10 days ago

XENE
Wall Street Analysts See a 48.15% Upside in Xenon Pharmaceuticals (XENE): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 48.2% in Xenon Pharmaceuticals (XENE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks 10 days ago

XENE
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, British Columbia and BOSTON, May 02, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced equity inducement grants to four new non-officer employees consisting of an aggregate of 78,600 share options and 1,800 performance share units (“PSUs”). All of the foregoing share options and PSUs were approved by th

GlobeNewswire 13 days ago

XENE
Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025

Three epilepsy posters to be presented in scientific sessions at the American Academy of Neurology meetingLong-term 36-month data from the ongoing X-TOLE OLE study of azetukalner in focal onset seizures (FOS)Exploratory analysis of efficacy of azetukalner in FOS seizure sub-typesPatient survey findings on mental health and comorbidity burdens of FOS VANCOUVER, British Columbia and BOSTON, April 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biophar

GlobeNewswire last month

XENE
Xenon to Present at Stifel 2025 Virtual CNS Forum

VANCOUVER, British Columbia and BOSTON, March 12, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the Stifel 2025 Virtual CNS Forum taking place from March 18-19, 2025. Fireside Chat Presentation Details: Date:Wednesday, March 19, 2025 Time:12:00-12:25 PM Eastern Time Webcast:Reg

GlobeNewswire 2 months ago

XENE
Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus

XENE reports a narrower-than-expected fourth-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.

Zacks 2 months ago

XENE
Xenon Pharmaceuticals Inc (XENE) Q4 2024 Earnings Call Highlights: Strategic Advancements and ...

Xenon Pharmaceuticals Inc (XENE) showcases robust pipeline progress and financial stability, while addressing challenges in clinical trial enrollments and market competition.

GuruFocus.com 2 months ago

XENE
Xenon Pharmaceuticals: Q4 Earnings Snapshot

On a per-share basis, the Burnaby, British Columbia-based company said it had a loss of 84 cents. The results beat Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss of 89 cents per share.

Associated Press Finance 2 months ago

XENE
Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update

– Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch – First of three planned Phase 3 azetukalner MDD studies underway, with second study on track to initiate mid-year – Phase 3 azetukalner bipolar depression program planned for clinical trial initiation mid-year – Early-stage portfolio advancing with Kv7 and Nav1.7 IND filings anticipated in 2025 – Neurocrine collaboration achieves milestone with initiation of

GlobeNewswire 2 months ago

XENE
Xenon to Present at the 45th Annual TD Cowen Healthcare Conference

VANCOUVER, British Columbia and BOSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the 45th Annual TD Cowen Healthcare Conference taking place in Boston, MA from March 3-5, 2025. Fireside Chat Presentation Details: Date:Tuesday, March 4, 2025 Time:10:30-11:00 AM Eas

GlobeNewswire 2 months ago

XENE
Xenon to Report Q4 and Full Year 2024 Financial Results on February 27, 2025

VANCOUVER, British Columbia and BOSTON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its fourth quarter 2024 financial results after the close of U.S. financial markets on Thursday, February 27, 2025. Conference Call/Webcast Information: Date:Thursday, February 27, 2025 Time:4:30 pm Ea

GlobeNewswire 2 months ago

XENE
We're Not Very Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Simply Wall St. 3 months ago

XENE
Xenon Outlines Key Corporate Milestone Opportunities for 2025

– Topline data from the first Phase 3 FOS study anticipated in H2 2025 representing major milestone in support of NDA filing and potential launch of azetukalner – First of three planned Phase 3 MDD studies now initiated – Expanding ion channel portfolio includes Kv7 and Nav1.7 candidates advancing towards IND filings in 2025 VANCOUVER, British Columbia and BOSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicat

GlobeNewswire 3 months ago

XENE
Xenon to Present at the 43rd Annual J.P. Morgan Healthcare Conference

VANCOUVER, British Columbia and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference taking place in San Francisco, CA from January 13-16, 2025. Company Presentation Details: Date:Monday, January 13, 2025Time:9:45-10:2

GlobeNewswire 4 months ago

XENE

Performance Overview

Return	XP0.F	S&P 500 (^GSPC)
YTD	-29.19%	+0.60%
1-Year	-29.19%	+11.70%
3-Year	-7.75%	+47.63%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Xenon Pharmaceuticals Inc. (XP0.F)

Xenon to Present at the 2025 RBC Capital Markets Global Healthcare Conference

Why Xenon Pharmaceuticals Inc. (XENE) Declined on Tuesday

Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus

Xenon Pharmaceuticals Inc (XENE) Q1 2025 Earnings Call Highlights: Strong Financial Position ...

Xenon Pharmaceuticals: Q1 Earnings Snapshot

Xenon Reports First Quarter 2025 Financial Results and Provides Business Update

Xenon to Report Q1 2025 Financial Results on May 12, 2025

Wall Street Analysts See a 48.15% Upside in Xenon Pharmaceuticals (XENE): Can the Stock Really Move This High?

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025

Xenon to Present at Stifel 2025 Virtual CNS Forum

Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus

Xenon Pharmaceuticals Inc (XENE) Q4 2024 Earnings Call Highlights: Strategic Advancements and ...

Xenon Pharmaceuticals: Q4 Earnings Snapshot

Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update

Xenon to Present at the 45th Annual TD Cowen Healthcare Conference

Xenon to Report Q4 and Full Year 2024 Financial Results on February 27, 2025

We're Not Very Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Rate

Xenon Outlines Key Corporate Milestone Opportunities for 2025

Xenon to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Performance Overview